InvestorsHub Logo
Followers 0
Posts 43
Boards Moderated 0
Alias Born 07/02/2017

Re: None

Tuesday, 07/18/2017 7:14:28 PM

Tuesday, July 18, 2017 7:14:28 PM

Post# of 18649

Some interesting pieces from this link

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3519950/

"Moreover, CD107a expression induced by the TriKE was significantly greater than the levels induced by rituximab. To evaluate whether this increased function was due to the surface expression levels of CD19, CD20 and CD22 on the primary ALL, CLL and AML leukemia targets, expression of these B-cell antigens was measured via FACS analysis (Figures 6B and 6C). Variations in surface expression of these receptors between patient samples were observed within each type of primary leukemia. The overall CD19, CD20 and CD22 expression profile of the primary leukemia targets suggests there may be an advantage to targeting two tumor-antigens rather than one."

"ALL and CLL tumors. Notably, the TriKE was significantly superior to rituximab in targeting of ALL and CLL. "

Rituxan has annual sales of 5 billion.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent GTBP News